Oracle buys Relsys
Oracle is to acquire Relsys International (Relsys), a provider of drug safety and risk management solutions with advanced analytics for the health sciences industry.
Relsys’ solutions are designed to support adverse event reporting, risk management, and data analysis for pharmaceutical, biotechnology, contract research organisations and medical device companies worldwide.
The combination of Oracle and Relsys is expected to deliver the only suite of software applications that supports end-to-end drug safety processes across clinical development, post-market surveillance and patient care.
The addition of Relsys will bring significant domain knowledge and experience as part of Oracle’s Health Sciences Global Business Unit, and is consistent with Oracle’s strategy to provide mission-critical applications for key industries.
The transaction is subject to customary closing conditions and is expected to close in the first half of this year.
Until the deal closes, each company will continue to operate independently.
Financial details of the transaction were not disclosed.